GEHC vs BMY
organic revenue · Bristol-Myers Squibb
| GEHC organic revenue Healthcare | BMY Bristol-Myers Squibb Healthcare | |
|---|---|---|
| Market | ||
| Price | $79.56 +0.01% | $63.17 +0.24% |
| Market cap | $34.6B | $128.0B |
| P/E (TTM) | 17.4 | 13.8 |
| Dividend yield | 0.16% | 4.58% |
| 52-week range | $58.75 – $89.77 | $43.20 – $68.64 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | GE HealthCare Expanded Margin 180 Basis Points, With A $55M Tariff Refund Nov 3, 2026 | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | $13.1 billion +7% YoY |
| EPS | — | $1.05 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +7% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.